Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 8, 2026

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

Amyloid imaging in clinical trials.

Rik Ossenkoppele1, Niels D Prins2, Bart Nm van Berckel3

  • 1Department of Radiology & Nuclear Medicine, VU University Medical Center Amsterdam, PO Box 7057, 1007 MB, Amsterdam, the Netherlands ; Alzheimer Center & Department of Neurology, VU University Medical Center, Amsterdam, PO Box 7057, 1007 MB, Amsterdam, the Netherlands.

Alzheimer'S Research & Therapy
|August 20, 2013
PubMed
Summary

Related Concept Videos

Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

A probabilistic framework for clinicopathological Alzheimer's disease using tau-PET.

Alzheimer's research & therapy·2026
Same author

The potential of key Alzheimer's plasma biomarkers to mimic tau PET MUBADA-based disease staging.

Alzheimer's research & therapy·2026
Same author

Improving the clinical trial landscape for patients with atypical variants of Alzheimer's disease: a call to action.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Plasma eMTBR-tau243 and %p-tau217 for Biological Staging of Alzheimer Disease.

JAMA neurology·2026
Same author

Tau-PET and CSF MTBR-tau243 comparisons validate increased tau aggregation in females.

European journal of nuclear medicine and molecular imaging·2026
Same author

Proteomic signatures of the APOE ε4 and APOE ε2 genetic variants and Alzheimer's disease.

Nature aging·2026

Accurate amyloid imaging is crucial for Alzheimer's disease clinical trials. New quantitative methods are proposed to reliably track changes in amyloid burden over time, improving drug efficacy assessment.

Area of Science:

  • Neuroimaging
  • Alzheimer's Disease Research
  • Pharmacodynamics

Background:

  • In vivo amyloid-beta imaging is vital for Alzheimer's disease (AD) clinical trials, especially for disease-modifying agents.
  • Accurate monitoring of amyloid burden changes is essential for evaluating the efficacy of anti-amyloid therapies.
  • Current imaging methods are suboptimal, failing to account for disease-related and drug-induced alterations in cerebral blood flow.

Purpose of the Study:

  • To address practical and methodological challenges in longitudinal amyloid imaging for AD.
  • To propose improved quantitative analytical methods for assessing changes in amyloid burden over time.
  • To enhance the reliability of amyloid imaging in clinical trials for Alzheimer's disease.

Main Methods:

  • Discussion of current limitations in longitudinal amyloid imaging techniques.

Related Experiment Videos

Last Updated: May 8, 2026

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

  • Proposal of quantitative, feasible alternatives for assessing amyloid burden.
  • Focus on accounting for heterogeneous changes in cerebral blood flow.

    • Main Results:

    • Identified suboptimal methodologies in current amyloid imaging practices.
    • Highlighted the need for advanced analytical approaches to capture dynamic changes in amyloid burden.
    • Presented potential quantitative methods for more accurate longitudinal assessment.

    Conclusions:

    • Improved analytical methods are necessary for reliable assessment of amyloid burden in AD clinical trials.
    • Quantitative approaches that consider physiological changes are key to evaluating anti-amyloid therapies.
    • The proposed methods offer a path towards more precise monitoring of therapeutic effects in Alzheimer's disease research.